Search Results 21-30 of 27666 for Proto-oncogene
(ALK), B-Raf proto-oncogene (BRAF) or ROS proto-oncogene 1 (ROS1) mutations who have not received appropriate therapies targeting these mutations and ...
The study, published in the Sept. 10 issue of Cancer Cell, overturns the current belief that a mutation in the KRAS oncogene is enough to initiate pancreatic ...
... oncogene drives tumorigenesis, and to evaluate novel therapeutic intervention strategies targeting PKCι for improved treatment of these cancers. In this ...
The investigative team developed a novel zebrafish model of neuroblastoma metastasis by overexpressing the human MYCN oncogene and knocking out the GAS7 gene.
Molecular characterization may include short tandem DNA repeat; STR) and oncogenic/tumor suppressor gene mutation analyses to assure that the derived models ...
The Epigenetic Etiology of Human Disease Laboratory at Mayo Clinic is studying epigenetic mutations at the epigenome and transcriptome levels.
In this uncommon and aggressive type of cancer, doctors aren't sure where the cancer began. Learn how they determine which treatments are most likely to ...
ROCHESTER, Minn. — The human cell cycle, the normal process of replication by which cells divide, separate and become two, is also a juncture where many ...
While PKD1 mediates cell proliferation and also acts as a suppressor of breast tumor cell invasion, PKD3, when expressed, mediates all oncogenic functions.
Overview · Describing a paradigm shift for the tumor suppressor FoxO3a, whereby our research team identified a new oncogenic role promoting tumor growth ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.